Burns: Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 14, Issue 2, 2011, Pages 176-181

  Gauglitz, Gerd G ^a   Williams, Felicia N ^b   Herndon, David N ^b,c   Jeschke, Marc G ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

critical illness; glucose; nutrition; propranolol

Indexed keywords

ANTIDIABETIC AGENT; CATECHOLAMINE; FENOFIBRATE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HUMAN GROWTH HORMONE; HYDROCORTISONE; INCRETIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; KETOCONAZOLE; METFORMIN; MUSCLE PROTEIN; NITROGEN; OXANDROLONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROPRANOLOL; RECOMBINANT INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN; UNCLASSIFIED DRUG;

ACUTE BURN; ARTICLE; BLOOD GLUCOSE MONITORING; BURN; BURN PATIENT; CATECHOLAMINE BLOOD LEVEL; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG MEGADOSE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERMETABOLISM; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LACTIC ACIDOSIS; LOW DRUG DOSE; NITROGEN BALANCE; THERMOGENESIS; VENTILATED PATIENT;

ANABOLIC AGENTS; BLOOD GLUCOSE; BURNS; GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; OXANDROLONE; PROPRANOLOL;

EID: 79952039952     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3283428df1     Document Type: Article

References (48)

1. Mongardon N, Singer M. The evolutionary role of nutrition and metabolic support in critical illness. Crit Care Clin 2010;26:443-450;vii-viii.
2. Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg 2008;248:387-401.
3. Goldstein DS, Kopin IJ. Evolution of concepts of stress. Stress 2007;10:109-120. (Pubitemid 46789482)
4. Williams FN, Herndon DN, Hawkins HK, et al. The leading causes of death after burn injury in a single pediatric burn center. Crit Care 2009;13:R183.
5. Williams FN, Jeschke MG, Chinkes DL, et al. Modulation of the hypermetabolic response to trauma: temperature, nutrition, and drugs. J Am Coll Surg 2009;208:489-502.
6. Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by betablockade after severe burns. N Engl J Med 2001;345:1223-1229. (Pubitemid 34951485)
7. Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000;128:312-319. (Pubitemid 30622500)
8. Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004;363:1895-1902. (Pubitemid 38748648)
9. Jeschke MG, Klein D, Thasler WE, et al. Insulin decreases inflammatory signal transcription factor expression in primary human liver cells after LPS challenge. Mol Med 2008;14:11-19. (Pubitemid 351356881)
10. Gauglitz GG, Herndon DN, Kulp GA, et al. Abnormal insulin sensitivity persists up to three years in pediatric patients postburn. J Clin Endocrinol Metab 2009;94:1656-1664.
11. Greenhalgh DG, Saffle JR, Holmes JHT, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007;28:776-790. (Pubitemid 350085032)
12. Murray CK, Loo FL, Hospenthal DR, et al. Incidence of systemic fungal infection and related mortality following severe burns. Burns 2008;34: 1108-1112.
13. Branski LK, Herndon DN, Barrow RE, et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann Surg 2009. [Epub ahead of print].
14. Wu X, Herndon DN, Wolf SE. Growth hormone down-regulation of Interleukin- 1beta and Interleukin-6 induced acute phase protein gene expression is associated with increased gene expression of suppressor of cytokine signal-3. Shock 2003;19:314-320.
15. Heszele MF, Price SR. Insulin-like growth factor I: the yin and yang of muscle atrophy. Endocrinology 2004;145:4803-4805. (Pubitemid 39551093)
16. Jeschke MG, Herndon DN, Barrow RE. Insulin-like growth factor I in combination with insulin-like growth factor binding protein 3 affects the hepatic acute phase response and hepatic morphology in thermally injured rats. Ann Surg 2000;231:408-416. (Pubitemid 30137129)
17. Spies M, Wolf SE, Barrow RE, et al. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit Care Med 2002;30:83-88. (Pubitemid 34112181)
18. Langouche L, Van den Berghe G. Glucose metabolism and insulin therapy. Crit Care Clin 2006;22:119-129;vii. (Pubitemid 43037113)
19. Jeschke MG, Finnerty CC, Suman OE, et al. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn. Ann Surg 2007;246:351-360;discussion 360-362. (Pubitemid 47312118)
20. Wolf SE, Edelman LS, Kemalyan N, et al. Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial. J Burn Care Res 2006;27:131-139;discussion 140-141. (Pubitemid 43970312)
21. Przkora R, Herndon DN, Suman OE. The effects of oxandrolone and exercise on muscle mass and function in children with severe burns. Pediatrics 2007;119:e109-e116. (Pubitemid 46397813)
22. Al-Mousawi AM, Williams FN, Mlcak RP, et al. Effects of exercise training on resting energy expenditure and lean mass during pediatric burn rehabilitation. J Burn Care Res 2010;31:400-408.
23. Williams FN, Herndon DN, Kulp GA, et al. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery 2010. [Epub ahead of print]
24. Barrow RE, Wolfe RR, Dasu MR, et al. The use of beta-adrenergic blockade in preventing trauma-induced hepatomegaly. Ann Surg 2006;243:115-120. (Pubitemid 43054063)
25. Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp 2007;280:238-248;discussion 248-251.
26. Pidcoke HF, Wade CE, Wolf SE. Insulin and the burned patient. Crit Care Med 2007;35:S524-S530. (Pubitemid 47312189)
27. Thomas SJ, Morimoto K, Herndon DN, et al. The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn. Surgery 2002;132:341-347. (Pubitemid 35024782)
28. Jeschke MG, Klein D, Herndon DN. Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg 2004;239:553-560. (Pubitemid 38372772)
29. Dandona P, Chaudhuri A, Mohanty P, et al. Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care 2007;10:511-517. (Pubitemid 46934123)
30. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-1367.
31. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-461. (Pubitemid 43200296)
32. Ellger B, Debaveye Y, Vanhorebeek I, et al. Survival benefits of intensive insulin therapy in critical illness: impact ofmaintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 2006;55:1096-1105. (Pubitemid 44100187)
33. Ingels C, Debaveye Y, Milants I, et al. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J 2006;27: 2716-2724. (Pubitemid 44729874)
34. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139.
35. Langouche L, Vanhorebeek I, Van den BergheG. Therapy insight: the effect of tight glycemic control in acute illness. Nat Clin Pract Endocrinol Metab 2007;3:270-278.
36. Finney SJ, Zekveld C, Elia A, et al. Glucose control and mortality in critically ill patients. JAMA 2003;290:2041-2047. (Pubitemid 37430587)
37. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign, 2008: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008;36:296-327.
38. Gore DC, Wolf SE, Herndon DN, et al. Metformin blunts stress-induced hyperglycemia after thermal injury. J Trauma 2003;54:555-561. (Pubitemid 36383756)
39. Gore DC, Herndon DN, Wolfe RR. Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J Trauma 2005;59:316-322;discussion 322-323.
40. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-579. (Pubitemid 126537875)
41. Cree MG, Zwetsloot JJ, Herndon DN, et al. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 2007;245:214-221. (Pubitemid 46148480)
42. Deane AM, Chapman MJ, Fraser RJ, et al. The effect of exogenous glucagonlike peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009;13:R67.
43. Mecott GA, Herndon DN, Kulp GA, et al. The use of exenatide in severely burned pediatric patients. Crit Care 2010;14:R153.
44. Jeschke MG, Barrow RE, Herndon DN. Recombinant human growth hormone treatment in pediatric burn patients and its role during the hepatic acute phase response. Crit Care Med 2000;28:1578-1584. (Pubitemid 30324543)
45. Minnich A, Tian N, Byan L, et al. A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2001;280:E270-E279.
46. Schnabel D, Grasemann C, Staab D, et al. A multicenter, randomized, doubleblind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 2007;119: e1230-e1238. (Pubitemid 46871239)
47. Jeschke MG, Finnerty CC, Kulp GA, et al. Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. Pediatr Crit Care Med 2008;9:209-216. (Pubitemid 351355027)
48. Williams FN, Herndon DN, Jeschke MG. The hypermetabolic response to burn injury and interventions to modify this response. Clin Plast Surg 2009;36:583-596.